

# Application for Quotation of Additional Securities

File Reference:

I:\Issuers\Frms\website forms\documents 2016\issuers\NSX Quotation of Additional Securities.doc



<b>INTRODUCTION .....</b>	<b>2</b>
<b>NEW ISSUE ANNOUNCEMENT, APPLICATION FOR QUOTATION OF ADDITIONAL SECURITIES AND AGREEMENT .....</b>	<b>3</b>
<b>PART 1 - ALL ISSUES.....</b>	<b>3</b>
<b>PART 2 - BONUS ISSUE OR PRO RATA ISSUE.....</b>	<b>5</b>
<b>PART 3 - QUOTATION OF SECURITIES .....</b>	<b>7</b>
<b>ADDITIONAL SECURITIES FORMING A NEW CLASS OF SECURITIES .....</b>	<b>7</b>
<b>QUOTATION AGREEMENT .....</b>	<b>9</b>

# Introduction

To ensure the efficient processing of this form by NSX, please:

1. Adhere to the suggested number of the annexures required by this form.
2. Complete **all** statements and questions in this form. (NSX can provide an electronic version of this form on request).





## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to NSX as soon as available. Information and documents given to NSX become NSX's property and may be made public.*

Introduced 11 March 2004. Revised 7 March 2016.

Name of entity

Beroni Group Limited

ABN/ACN

613 077 526

We (the entity) give NSX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |   |                 |
|---|---|-----------------|
| 1 | Class of securities issued or to be issued  | Ordinary shares |
| 2 | Number of securities issued or to be issued (if known) or maximum number which may be issued  | 683,600         |
| 3 | Principal terms of the securities (eg, if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion)   | N/A             |
| 4 | <p>Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"><li>• the date from which they do</li><li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li><li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li></ul> | Yes             |





<b>5</b>	Issue price or consideration	Nil for patent acquisition. US\$2.50 for convertible notes.	
<b>6</b>	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Brain wave extraction patent acquisition and conversion of convertible note	
<b>7</b>	Dates of entering securities into uncertificated holdings or despatch of certificates	22 April 2025	
<b>8</b>	Number and class of all securities quoted on NSX (including the securities in clause 2 if applicable)	Number	Class
		20,115,597	Fully paid ordinary shares
<b>9</b>	Number and class of all securities not quoted on NSX (including the securities in clause 2 if applicable)	Number	Class
		8,761,685	FPO – Subject to Cleansing Prospectus
		2,485,000	Options exercisable at US\$5.00 expiring 30 June 2025
		883,125	Options exercisable at US\$6.00 expiring 30 June 2025
		887,500	Options exercisable at US\$7.00 expiring 30 June 2025
		1,068,125	Options exercisable at US\$9.00 expiring 30 June 2025
		20,736	Convertible Notes
<b>10</b>	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	



11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the securities will be offered	
14	Class of securities to which the offer relates	
15	Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new issue documents  <small>Note: Security holders must be told how their entitlements are to be dealt with.</small>	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	



- ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■



*You need only complete this section if you are applying for quotation of securities*

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

--



- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

[illegible]

(if issued upon conversion of another security, clearly identify that other security)

Number	Class



## Quotation agreement

1 Quotation of our additional securities is in NSX's absolute discretion. NSX may quote the securities on any conditions it decides.

2 We warrant the following to NSX.

- The issue of the securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those securities should not be granted quotation.
- An offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

**Note:** An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any securities to be quoted and that no-one has any right to return any securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the securities to be quoted, it has been provided at the time that we request that the securities be quoted.
- If we are a trust, we warrant that no person has the right to return the securities to be quoted under section 1019B of the Corporations Act at the time that we request that the securities be quoted.

3 We will indemnify NSX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give NSX the information and documents required by this form. If any information or document not available now, will give it to NSX before quotation of the securities begins. We acknowledge that NSX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



(Director/Company secretary)

Date: ... 23 April 2025.....

Print name: ..Chen Chik Ong.....